Glyburide: A Second‐generation Sulfonylurea Hypoglycemic Agent: History, Chemistry, Metabolism, Pharmacokinetics, Clinical Use and Adverse Effects
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Glyburide, a second‐generation hypoglycemic sulfonylurea, is 200 times as potent as tolbutamide. This increase is due to greater intrinsic hypoglycemic potency of the molecule rather than to a prolonged biologic half‐life. Glyburide is inactivated by the liver to 4‐trans‐hydroxyglyburide and 3‐cis‐hydroxyglyburide; 50% of these compounds is excreted in the urine and 50% in the bile. Although the serum concentration of glyburide can be measured by radioimmunoassay and high‐performance liquid chromatography, the importance of its serum concentration in the reduction of hyperglycemia is not yet established. Glyburide has a therapeutic effectiveness comparable to that of the first‐generation sulfonylurea chlorpropamide; however, it has a lower frequency of adverse effects. To date it has a low frequency of clinically significant interactions with other drugs. Glyburide should not be prescribed for patients with liver disease or significant renal disease. Because glyburide is a potent hypoglycemic agent, it should be prescribed in small initial doses, particularly for elderly patients with diabetes. At the present time there is no definite evidence that it modifies the increased risk of cardiovascular disease of diabetic patients. Although glyburide is a potent stimulator of pancreatic insulin secretion after short‐term administration, an additional mechanism of action during long‐term administration is to decrease the resistance of muscle and liver to the action of insulin. It is a useful medication for patients with type II diabetes whose hyperglycemia is not adequately reduced by dietary management and exercise. It can be used as the initial drug in these patients or as the replacement drug for those with primary or secondary failure during therapy with first‐generation sulfonylureas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
The Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic Subjects
Kolterman, O. G., Gray, R. S., Shapiro, G., Scarlett, J. A., Griffin, J., & Olefsky, J. M. (1984) · Diabetes · doi:10.2337/diab.33.4.346 · Cited by 213
Cited by
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
Matthaei, S., Stumvoll, M., Kellerer, M., & Häring, H.-U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0413 · Cited by 377
The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus
Rendell, M. (2004) · Drugs · doi:10.2165/00003495-200464120-00006 · Cited by 308
Snyder, R. W., & Berns, J. S. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17346.x · Cited by 215
“Glyburide undergoes extensive hepatic metabolism to several metabolites that undergo equal biliary and renal excretion (10,16,34).”
BackgroundPugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Pharmacokinetics, efficacy and safety of glyburide for treatment of gestational diabetes mellitus
Malek, R., & Davis, S. N. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1187131 · Cited by 54
“3 and is ionized in plasma.[14] These characteristics impact transplacental transfer.”
Background
Metadata
- Authors
- Feldman, J. M.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 1985-03-04
- Volume
- 5
- Issue
- 2
- Pages
- 43-62
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W1906349732
- Cited by
- 104
- References
- 2
- FWCI
- 1.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glyburide: A Second‐generation Sulfonylurea Hypoglycemic Agent: History, Chemistry, Metabolism, Pharmacokinetics, Clinical Use and Adverse Effects. https://app.cochat.ai/papers/10.1002/j.1875-9114.1985.tb03404.x
- The paper
- Feldman, J. M. (1985). Glyburide: A Second‐generation Sulfonylurea Hypoglycemic Agent: History, Chemistry, Metabolism, Pharmacokinetics, Clinical Use and Adverse Effects. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/j.1875-9114.1985.tb03404.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.